BACKGROUND/AIMS: Insulin like growth factor system becomes impaired in liver cirrhosis. Hepatocellular carcinoma (HCC) is associated with altered synthesis and secretion of several growth factors. METHODOLOGY: Studying the relation between serum levels of IGF-I, IGF-II and IGFBP-3 and clinical grades of liver disease according to Child-Pugh (C-P) score. Also, evaluation of their role in the diagnosis of HCC. IGF-I, IGF-II and IGFBP-3 were measured in 20 healthy subjects, 60 liver cirrhosis patients and 20 HCC patients included in the study. RESULTS: IGF-I, IGF-II and IGFBP-3 levels were significantly lower in cirrhotic patients compared to the healthy subjects and were correlated with the degree of liver dysfunction. IGF-I and IGFBP-3 levels in patients with HCC were significantly lower than in both healthy subjects and in patients with liver cirrhosis. Both IGF-II and AFP levels in HCC were significantly higher than in healthy subjects and in patients with liver cirrhosis. CONCLUSIONS: Estimation of serum IGF-I, IGF-II and IGFBP-3 together with C-P score is more effective in predicting hepatic dysfunction and its severity than C-P score alone. Serum IGF-II level can be used as a serological marker to discriminate HCC from cirrhosis.
BACKGROUND/AIMS: Insulin like growth factor system becomes impaired in liver cirrhosis. Hepatocellular carcinoma (HCC) is associated with altered synthesis and secretion of several growth factors. METHODOLOGY: Studying the relation between serum levels of IGF-I, IGF-II and IGFBP-3 and clinical grades of liver disease according to Child-Pugh (C-P) score. Also, evaluation of their role in the diagnosis of HCC. IGF-I, IGF-II and IGFBP-3 were measured in 20 healthy subjects, 60 liver cirrhosispatients and 20 HCC patients included in the study. RESULTS:IGF-I, IGF-II and IGFBP-3 levels were significantly lower in cirrhotic patients compared to the healthy subjects and were correlated with the degree of liver dysfunction. IGF-I and IGFBP-3 levels in patients with HCC were significantly lower than in both healthy subjects and in patients with liver cirrhosis. Both IGF-II and AFP levels in HCC were significantly higher than in healthy subjects and in patients with liver cirrhosis. CONCLUSIONS: Estimation of serum IGF-I, IGF-II and IGFBP-3 together with C-P score is more effective in predicting hepatic dysfunction and its severity than C-P score alone. Serum IGF-II level can be used as a serological marker to discriminate HCC from cirrhosis.
Authors: Jennifer Mitchell; Peggy T Tinkey; Rony Avritscher; Carolyn Van Pelt; Ghazaleh Eskandari; Suraj Konnath George; Lianchun Xiao; Erik Cressman; Jeffrey S Morris; Asif Rashid; Ahmed O Kaseb; Hesham M Amin; Rajesh Uthamanthil Journal: Oncology Date: 2016-06-16 Impact factor: 2.935
Authors: Veeral Ajmera; Emily R Perito; Nathan M Bass; Norah A Terrault; Katherine P Yates; Ryan Gill; Rohit Loomba; Anna Mae Diehl; Bradley E Aouizerat Journal: Hepatology Date: 2016-10-12 Impact factor: 17.425
Authors: Reham Abdel-Wahab; Manal M Hassan; Bhawana George; Roberto Carmagnani Pestana; Lianchun Xiao; Sahin Lacin; Suayib Yalcin; Ahmed S Shalaby; Humaid O Al-Shamsi; Kanwal Raghav; Robert A Wolff; James C Yao; Lauren Girard; Abedul Haque; Dan G Duda; Simona Dima; Irinel Popescu; Hesham A Elghazaly; Jean-Nicolas Vauthey; Thomas A Aloia; Ching-Wei Tzeng; Yun Shin Chun; Asif Rashid; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb Journal: Oncology Date: 2020-10-07 Impact factor: 2.935